|
1
|
Clarke CA, Glaser SL, Leung R,
Davidson-Allen K, Gomez SL and Keegan TH: Prevalence and
characteristics of cancer patients receiving care from single vs.
multiple institutions. Cancer epidemiol. 46:27–33. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Narayanan R and Dalton JT: Androgen
receptor: A complex therapeutic target for breast cancer. Cancers
(Basel). 8:pii: E1082016. View Article : Google Scholar
|
|
3
|
Friese CR, Li Y, Bondarenko I, Hofer TP,
Ward KC, Hamilton AS, Deapen D, Kurian AW and Katz SJ: Chemotherapy
decisions and patient experience with the recurrence score assay
for early-stage breast cancer. Cancer. 123:43–51. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cata JP, Chavez-MacGregor M, Valero V,
Black W, Black DM, Goravanchi F, Ifeanyi IC, Hernandez M,
Rodriguez-Restrepo A and Gottumukkala V: The impact of
paravertebral block analgesia on breast cancer survival after
surgery. Reg Anesth Pain Med. 41:696–703. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mikkola TS, Savolainen-Peltonen H,
Tuomikoski P, Hoti F, Vattulainen P, Gissler M and Ylikorkala O:
Reduced risk of breast cancer mortality in women using
postmenopausal hormone therapy: A Finnish nationwide comparative
study. Menopause. 23:1199–1203. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sato Y: The vasohibin family.
Pharmaceuticals (Basel). 3:433–440. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li Z, Tu M, Han B, Gu Y, Xue X, Sun J, Ge
Q, Miao Y, Qian Z and Gao W: Vasohibin 2 decreases the cisplatin
sensitivity of hepatocarcinoma cell line by downregulating p53.
PLoS One. 9:e903582014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xue X, Zhang Y, Zhi Q, Tu M, Xu Y, Sun J,
Wei J, Lu Z, Miao Y and Gao W: MiR200-upregulated Vasohibin 2
promotes the malignant transformation of tumors by inducing
epithelial-mesenchymal transition in hepatocellular carcinoma. Cell
Commun Signal. 12:622014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kim JC, Kim KT, Park JT, Kim HJ, Sato Y
and Kim HS: Expression of vasohibin-2 in pancreatic ductal
adenocarcinoma promotes tumor progression and is associated with a
poor clinical outcome. Hepatogastroenterology. 62:251–256.
2015.PubMed/NCBI
|
|
10
|
Koyanagi T, Suzuki Y, Saga Y, Machida S,
Takei Y, Fujiwara H, Suzuki M and Sato Y: In vivo delivery of siRNA
targeting vasohibin-2 decreases tumor angiogenesis and suppresses
tumor growth in ovarian cancer. Cancer Sci. 104:1705–1710. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Koyanagi T, Saga Y, Takahashi Y, Suzuki Y,
Suzuki M and Sato Y: Downregulation of vasohibin-2, a novel
angiogenesis regulator, suppresses tumor growth by inhibiting
angiogenesis in endometrial cancer cells. Oncol Lett. 5:1058–1062.
2013.PubMed/NCBI
|
|
12
|
Tu M, Liu X, Han B, Ge Q, Li Z, Lu Z, Wei
J, Song G, Cai B, Lv N, et al: Vasohibin-2 promotes proliferation
in human breast cancer cells via upregulation of fibroblast growth
factor-2 and growth/differentiation factor-15 expression. Mol Med
Rep. 10:663–669. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tu M, Lu C, Lv N, Wei J, Lu Z, Xi C, Chen
J, Guo F, Jiang K, Li Q, et al: Vasohibin 2 promotes human luminal
breast cancer angiogenesis in a non-paracrine manner via
transcriptional activation of fibroblast growth factor 2. Cancer
Lett. 383:272–281. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Takahashi Y, Koyanagi T, Suzuki Y, Saga Y,
Kanomata N, Moriya T, Suzuki M and Sato Y: Vasohibin-2 expressed in
human serous ovarian adenocarcinoma accelerates tumor growth by
promoting angiogenesis. Mol Cancer Res. 10:1135–1146. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhao M, Yu S and Zhang M: Differential
expression of multidrug resistance-related proteins in
adriamycin-resistant (pumc-91/ADM) and parental (pumc-91) human
bladder cancer cell lines. Mol Med Rep. 14:4741–4746. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cetin I and Topcul MR: In vitro
antiproliferative effects of nab-paclitaxel with liposomal
cisplatin on MDA-MB-231 and MCF-7 breast cancer cell lines. J BUON.
22:347–354. 2017.PubMed/NCBI
|
|
17
|
Sui H, Zhou LH, Zhang YL, Huang JP, Liu X,
Ji Q, Fu XL, Wen HT, Chen ZS, Deng WL, et al: Evodiamine suppresses
ABCG2 mediated drug resistance by inhibiting p50/p65 NF-κB pathway
in colorectal cancer. J Cell Biochem. 117:1471–1481. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sun Y, Gu M, Zhu L, Liu J, Xiong Y, Wei Y
and Li F: Gemcitabine upregulates ABCG2/BCRP and modulates the
intracellular pharmacokinetic profiles of bioluminescence in
pancreatic cancer cells. Anticancer Drugs. 27:183–191. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dahlmann M, Okhrimenko A, Marcinkowski P,
Osterland M, Herrmann P, Smith J, Heizmann CW, Schlag PM and Stein
U: RAGE mediates S100A4-induced cell motility via MAPK/ERK and
hypoxia signaling and is a prognostic biomarker for human
colorectal cancer metastasis. Oncotarget. 5:3220–3233. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li N, Cui J, Duan X, Chen H and Fan F:
Suppression of type I collagen expression by miR-29b via PI3K, Akt,
and Sp1 pathway in human Tenon's fibroblasts. Invest Ophthalmol Vis
Sci. 53:1670–1678. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Miao B and Degterev A: Targeting
phospshatidylinositol 3-kinase signaling with novel
phosphatidylinositol 3,4,5-triphosphate antagonists. Autophagy.
7:650–651. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hu CF, Huang YY, Wang YJ and Gao FG:
Upregulation of ABCG2 via the PI3K-Akt pathway contributes to
acidic microenvironment-induced cisplatin resistance in A549 and
LTEP-a-2 lung cancer cells. Oncol Rep. 36:455–461. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
He X, Wang J, Wei W, Shi M, Xin B, Zhang T
and Shen X: Hypoxia regulates ABCG2 activity through the
activivation of ERK1/2/HIF-1α and contributes to chemoresistance in
pancreatic cancer cells. Cancer Biol Ther. 17:188–198. 2016.
View Article : Google Scholar : PubMed/NCBI
|
